Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.80 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.68 |
| ▸ | MPC2 | O95563 | 1/20 | 0.64 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932355 | 0.93 | PPARG (0.79) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL6928264 | 0.91 | PPARG (0.75) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL6931380 | 0.91 | PPARG (0.75) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL6929632 | 0.91 | PPARG (0.75) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL19217858 | 0.90 | PPARG (0.73) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL19217587 | 0.90 | PPARG (0.76) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL935983 | 0.89 | PPARG (1.00) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL12517394 | 0.89 | PPARG (0.81) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL6928620 | 0.89 | PPARG (1.00) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL6929481 | 0.89 | PPARG (1.00) | PPARGFFAR1MPC2CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202401-B1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CIRIUS THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-9126959-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8912335-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20120316138-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120309975-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309975-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885FFAR1 51/4885MPC2 131/4885 |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885FFAR1 51/4885MPC2 131/4885 |
| US-20120316138-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | PPARD, PPARA, PPARG | PPARG 3/4885FFAR1 45/4885MPC2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.